SCHEMBL165158

SCHEMBL165158

Cc1cc(F)ccc1[Mg]Br

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.35
ALDH1A1 P00352 2/20 0.31
MAPT P10636 1/20 0.31
PTGS1 P23219 3/20 0.31
PTGS2 P35354 3/20 0.31
ALOX5 P09917 1/20 0.31
KDM4E B2RXH2 1/20 0.30
HDAC4 P56524 1/20 0.30
CA3 P07451 1/20 0.30
CA6 P23280 1/20 0.30
CA5A P35218 1/20 0.30
CA9 Q16790 1/20 0.30
CA14 Q9ULX7 1/20 0.30
CA5B Q9Y2D0 1/20 0.30
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
KMT2A Q03164 1/20 0.30
NISCH Q9Y2I1 1/20 0.30
CYP1A2 P05177 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29435946 1.00 ACHE (0.35) ACHEALDH1A1MAPTPTGS1PTGS2
SCHEMBL379916 0.82 ACHE (0.35) ACHEALDH1A1MAPTPTGS1PTGS2
SCHEMBL362051 0.76 ALDH1A1 (0.42) ALDH1A1KDM4ECA3CA6CA5A
SCHEMBL29766167 0.76 ALDH1A1 (0.42) ALDH1A1KDM4ECA3CA6CA5A
SCHEMBL1021714 0.76 TDP1 (0.42) ACHEALDH1A1MEN1NPC1RAB9A
SCHEMBL21352050 0.73 NISCH (0.33) ALDH1A1CA3CA6CA5ACA9
SCHEMBL362696 0.73 CYP3A4 (0.41) ALDH1A1CYP2A6
SCHEMBL5637248 0.72 NFE2L2 (0.38) MAPTPTGS1KDM4ECA9CA14
SCHEMBL6423318 0.72 CYP3A4 (0.32)
SCHEMBL1827509 0.71 CA3 (0.42) ALDH1A1KDM4ECA3CA6CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025242747-A1 MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS MERCK PATENT GMBH (DE) 2025-11-27 WO claimed
US-7273948-B2 Process of preparing esters and ethers of probucol and derivatives thereof ATHEROGENICS, INC. (US) 2007-09-25 US claimed
EP-1594824-A4 PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF ATHEROGENICS INC (US) 2007-04-04 EP claimed
EP-1594824-A2 PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF Atherogenics, Inc. (US) 2005-11-16 EP claimed
US-20040204485-A1 Process of preparing esters and ethers of probucol and derivatives thereof CRABTREE ACQUISITION CO, LLC 2004-10-14 US claimed
WO-2004062622-A2 PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF ATHEROGENICS, INC. (US) 2004-07-29 WO claimed
WO-2025242747-A1 MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS MERCK PATENT GMBH (DE) 2025-11-27 WO disclosed
US-20250217687-A1 OPTICALLY ADDRESSABLE MOLECULAR-SPIN QUBIT DILUTED IN A HOST MATRIX UNIV CHICAGO (US) 2025-07-03 US disclosed
CN-119841849-A Pyridone compound, synthesis method and application thereof 浙江大学 2025-04-18 CN disclosed
EP-3386968-B1 BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR COMPOUNDS UNIV ILLINOIS (US) 2025-04-02 EP disclosed
US-12054469-B2 Benzothiophene-based selective estrogen receptor downregulator compounds THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2024-08-06 US disclosed
CN-117976986-A Fluorine-containing rechargeable magnesium battery electrolyte and preparation method and application thereof 重庆大学 2024-05-03 CN disclosed
EP-3565558-B1 COMBINATION THERAPY WITH A SERD COMPOUND AND A CDK4/6 INHIBITOR FOR THE TREATMENT OF CANCER G1 THERAPEUTICS INC (US) 2023-12-06 EP disclosed
EP-1377558-A1 [1,4]-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS GLAXO GROUP LIMITED (GB) 2004-01-07 EP disclosed
WO-2003066635-A1 PIPERIDINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-08-14 WO disclosed
WO-2003066621-A1 PIPERIDINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF TACHYKININS GLAXO GROUP LIMITED (GB) 2003-08-14 WO disclosed
WO-2003066589-A1 PIPERIDYLCARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TACHYKINIM-MEDIATED DISEASES GLAXO GROUP LIMITED (GB) 2003-08-14 WO disclosed
EP-1326832-A1 CHEMICAL COMPOUNDS GLAXO GROUP LIMITED (GB) 2003-07-16 EP disclosed
WO-2002081457-A1 `1,4!-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS GLAXO GROUP LIMITED (GB) 2002-10-17 WO disclosed
WO-2002032867-A1 CHEMICAL COMPOUNDS GLAXO GROUP LIMITED (GB) 2002-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12054469-B2 Benzothiophene-based selective estrogen receptor downregulator compounds ESR1, ESR2, GPER1 ACHE 4788/4885ALDH1A1 1328/4885MAPT 942/4885
US-20040204485-A1 Process of preparing esters and ethers of probucol and derivatives thereof NR3C2, MGLL, GCG ACHE 4145/4885ALDH1A1 2574/4885MAPT 1606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.